Specialized knowledge in the field of bioactive peptides
ABOUT STABLOR
Stablor is the first-in-class Medical Food having demonstrated microbiome modulation properties on key obesity-related bacteria.
COMPOSITION
Specific blend of amino acids, milk biopeptides, micronutriments associated with a well balanced diet and a mild caloric restriction (12 weeks).
BUSINESS OPPORTUNITIES
Ready to launch. IP protection granted in major markets (USA, Europe).
CLINICAL DEVELOPMENT
3 studies
including pivotal international randomized study resulting in strong clinical results
SAFETY
- Clinically tested
- High safety profile
EFFICACY
- High fat loss specificity
- Lean mass preservation
ACTION ON
UNDERLYING CAUSES
- Inflammation decrease
- Microbiome modulation
To date, STABLOR is the first microbiome modulator against obesity
The family Christensenellaceae was significantly enriched in subjects with a lean BMI (<25) compared to those with an obese BMI
Source : Human genetics shape the gut microbiome. Cell, 2014
go back to the site
Christensenella minuta amendment reduced weight gain and altered the microbiome of recipient mice.
Source : Human genetics shape the gut microbiome. Cell, 2014
go back to the site
Discovery of 20 novel bacteria
« Christensenellaceae family » unclassified to date, with a high potential on weight loss and visceral fat loss (PATENTED)
Discovery of 20 novel bacteria unclassified to date, associated with a high potential on weight loss and visceral fat loss (PATENTED).
20% of species in the intestinal microbiota have now been characterized, but we still need to understand the other 80%.
go back to the site
On the strength of promising results obtained on STABLOR, LNC Therapeutics is heading a development projet called TEMYS PROJECT
In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials
Discover our selection
Find out more